Table 2.
Clinicopathological characteristics associated with overall survival outcomes in PDAC patients-Univariate Cox proportional hazard models.
| Factors | Cut-off | Univariate analysis | ||
|---|---|---|---|---|
| HR | 95% CI | p-value | ||
| Age, years | > 70 | 1.06 | 0.61–1.84 | 0.80 |
| Sex | Male | 0.76 | 0.43–1.32 | 0.30 |
| Tumor size, mm | > 40 | 1.95 | 1.09–3.48 | 0.03* |
| CEA, ng/ml | > 5 | 1.22 | 0.67–2.20 | 0.50 |
| CA19-9, U/ml | > 80 | 1.01 | 0.14–7.43 | 0.50 |
| Differentiation, poor** | Present | 1.71 | 0.98–3.00 | 0.06 |
| Venous invasion | Present | 1.39 | 0.34–5.71 | 0.60 |
| Lymphatic vessel invasion | Present | 1.37 | 0.77–2.41 | 0.30 |
| UICC T-status | ≥ T3 | 1.37 | 0.77–2.41 | 0.30 |
| UICC N-status | > N1 | 2.29 | 1.17–4.48 | 0.009* |
| UICC M-status | M1 | 1.43 | 0.61–3.37 | 0.40 |
| Stage | ≥ III | 2.45 | 1.19–5.04 | 0.008* |
| cGAS-STING expression | Positive | 0.47 | 0.27–0.82 | 0.008* |
UICC, Union for International Cancer Control; HR, Hazard Ratio; 95% CI, 95% Confidence Interval; *Indicates statistical significance, < 0.05; **Indicates the cases which contain poorly differentiated component in the specimen.